Detalhe da pesquisa
1.
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
bioRxiv
; 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328215
2.
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.
Mol Cancer Ther
; 21(4): 625-634, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131875
3.
Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Mol Cancer Res
; 20(3): 361-372, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799403
4.
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Blood Cancer J
; 12(7): 110, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853853
5.
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Clin Cancer Res
; 27(1): 342-354, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046519
6.
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies.
Mol Cancer Ther
; 20(7): 1270-1282, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33879555
7.
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Mol Cancer Ther
; 18(12): 2368-2380, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439712
8.
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.
ACS Med Chem Lett
; 10(12): 1674-1679, 2019 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857845
9.
Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies.
Clin Cancer Res
; 24(14): 3465-3474, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29615457
10.
Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates.
ACS Med Chem Lett
; 9(8): 838-842, 2018 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30128077
11.
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
J Med Chem
; 61(7): 2837-2864, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562737
12.
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.
Clin Cancer Res
; 24(17): 4297-4308, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29764854
13.
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Clin Cancer Res
; 12(16): 4908-15, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16914579
14.
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
J Med Chem
; 60(7): 2790-2818, 2017 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28296398
15.
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.
Clin Cancer Res
; 10(2): 739-50, 2004 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14760097
16.
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Clin Cancer Res
; 9(1): 327-37, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12538485
17.
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Mol Cancer Ther
; 2(5): 471-8, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12748309
18.
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Mol Cancer Ther
; 2(10): 1011-21, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14578466
19.
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Clin Exp Metastasis
; 20(8): 757-66, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14713109
20.
Design, structure-activity relationship, and in vivo characterization of the development candidate NVP-HSP990.
J Med Chem
; 57(21): 9124-9, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25368984